Table I.
Effect of TMZ on cardiac function measured by color Doppler ultrasound.
| Parameter | N (n=9) | C (n=8) | TMZ (n=8) |
|---|---|---|---|
| HR (bpm) | 388±43 | 366±40 | 355±53 |
| E/A | 1.78±0.34 | 1.57±0.33 | 1.65±0.29 |
| LVEF (%) | 66.6±4.8 | 59.4±4.3a | 58.5±6.2a |
| LVFS (%) | 39.1±4.2 | 33.5±4.2a | 32.8±4.4a |
| LVPW-d (mm) | 2.07±0.30 | 1.76±0.13a | 1.73±0.19a |
| LVPW-s (mm) | 2.75±0.26 | 2.33±0.29a | 2.37±0.24a |
| IVS-d (mm) | 1.74±0.28 | 1.51±0.19 | 1.54±0.15 |
| IVS-s (mm) | 2.74±0.46 | 2.41±0.31 | 2.28±0.20a |
Values are expressed as the mean ± standard deviation.
a
P<0.05 vs. N. C, diabetic control group; E/A, early diastolic mitral valve blood flow velocity E peak/late diastolic mitral valve blood flow velocity A peak; IVS-d, diastolic interventricular septum thickness; LV, left ventricular; LVEF, LV ejection fraction; LVFS, LV fractional shortening; LVPW-d, diastolic LV posterior wall; LVPW-s, systolic LV posterior wall; N, normal group; TMZ, trimetazidine.